Pretarget lymphoma therapy

Drug Profile

Pretarget lymphoma therapy

Alternative Names: Pretarget technology

Latest Information Update: 07 Apr 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Poniard Pharmaceuticals
  • Class Antibodies
  • Mechanism of Action CD20 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Apr 2004 NeoRx's Pretarget® technology has been licensed to Aletheon Pharmaceuticals worldwide
  • 24 Jul 2002 Discontinued - Phase-I for Non-Hodgkin's lymphoma in USA (unspecified route)
  • 25 Jun 2002 A phase I study has been added to the adverse events and Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top